COMMUNIQUÉS West-GlobeNewswire

-
Marrone Bio Innovations to Report Second Quarter 2019 Results on Thursday, August 8th at 4:30 p.m. Eastern Time
02/08/2019 - 22:05 -
Alphatec Holdings, Inc. Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
02/08/2019 - 22:05 -
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/08/2019 - 22:01 -
Skin Care & Laser Physicians of Beverly Hills Expands Physician Availability for Patients
02/08/2019 - 20:44 -
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
02/08/2019 - 20:00 -
Resverlogix Announces Loan Reduction and Extension
02/08/2019 - 18:02 -
Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2019
02/08/2019 - 18:00 -
Information on total number of voting rights and shares composing the share capital as at July 31st, 2019
02/08/2019 - 18:00 -
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
02/08/2019 - 17:45 -
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 31 Juillet 2019
02/08/2019 - 17:45 -
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
02/08/2019 - 17:45 -
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 31 Juillet 2019
02/08/2019 - 17:45 -
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
02/08/2019 - 17:44 -
AB Science annonce aujourd’hui les résultats de son étude de phase 3 évaluant le masitinib chez des patients atteints de mélanome non opérable ou métastatique de stade 3 ou stade 4
02/08/2019 - 17:44 -
Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs
02/08/2019 - 17:40 -
Ecomed Solutions Receives Innovative Technology Contract from Vizient for Its Novel Blood Management Device, HEMAsavR™
02/08/2019 - 16:00 -
BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq
02/08/2019 - 15:45 -
Wildflower Brands Closes on Private Placement
02/08/2019 - 15:30 -
Predictive Laboratories to Present New Endometriosis Discoveries in Three Presentations at Leading Scientific Conference Focused on Human Infertility
02/08/2019 - 15:15
Pages